Vesicare® 5 mg, film-coated tablet 30’s

Each tablet contains 5 mg solifenacin succinate, corresponding to 3.8 mg solifenacin.

Therapeutic indications

Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

Method of administration

Vesicare should be taken orally and should be swallowed whole with liquids. It can be taken with or without food.

KSh5,905.00

2 in stock

Added to wishlistRemoved from wishlist 0
SKU: NDDA-PILL-VESIC-05 Categories: ,

Method of administration

Adults, including the elderly

The recommended dose is 5 mg solifenacin succinate once daily. If needed, the dose may be increased to 10 mg solifenacin succinate once daily.

Paediatric population

The safety and efficacy of Vesicare in children have not yet been established. Therefore, Vesicare should not be used in children.

Patients with renal impairment

No dose adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance > 30 ml/min). Patients with severe renal impairment (creatinine clearance ≤ 30 ml/min) should be treated with caution and receive no more than 5 mg once daily (see Section 5.2).

Patients with hepatic impairment

No dose adjustment is necessary for patients with mild hepatic impairment. Patients with moderate hepatic impairment (Child-Pugh score of 7 to 9) should be treated with caution and receive no more than 5 mg once daily (see Section 5.2).

Potent inhibitors of cytochrome P450 3A4

The maximum dose of Vesicare should be limited to 5 mg when treated simultaneously with ketoconazole or therapeutic doses of other potent CYP3A4-inhibitors e.g. ritonavir, nelfinavir, itraconazole.

Vesicare® 5 mg, film-coated tablet 30’s
Vesicare® 5 mg, film-coated tablet 30’s

KSh5,905.00

Contact Us

PillPharm
Reset Password